Ozempic, which contains semaglutide as its active ingredient, has been associated with serious gastrointestinal problems, including gastroparesis (delayed stomach emptying) and pancreatitis
Long-term conclusions rely on extrapolation Marie Spreckley, obesity researcher and public health nutritionist at the University of Cambridge in England, who was not involved in the study, cautioned that the papers long-term conclusions rely on modeled projections, rather than observed data, as the follow-up period for stopping treatment with newer medicines is limited to about 12 months
Semaglutide began as a treatment for type 2 diabetes
It covers why GLP-1 drugs put muscle at risk, what the STEP trial data shows on lean mass changes, and why the scale alone cannot detect this problem.Read Part 1: Semaglutide & Muscle Loss Integrate InBody into your GLP-1 programme today Medical Disclaimer: This article is for informational and educational purposes only and is intended for healthcare professionals
Descarga nuestra app y actvalas para no perderte nuestro mejor contenido
